

## **Studio multicentrico RECOLT**

### **Publicazioni (Pub MED)**

1. Ponziani FR, Milani A, Gasbarrini A, Zaccaria R, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Cescon M, Burra P, Miglioresi L, Merli M, Paolo DD, Fagioli S, Pompili M; AISF RECOLT-C Group. Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. *Transpl Int.* 2013 Mar;26(3):281-9. doi: 10.1111/tri.12027. Epub 2012 Dec 11.
2. Ponziani FR, Milani A, Gasbarrini A, Zaccaria R, Viganò R, Donato MF, Morelli MC, Miglioresi L, Pasulo L, Rendina M, Paolo DD, Marino M, Toniutto P, Fagioli S, Pompili M. Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study. *Ann Hepatol.* 2012 May-Jun;11(3):338-42.
3. Giannelli V, Giusto M, Farcomeni A, Ponziani FR, Pompili M, Viganò R, Iemmolo RM, Donato MF, Rendina M, Toniutto P, Pasulo L, Morelli MC, De Martin E, Miglioresi L, Di Paolo D, Fagioli S, Merli M; AISF RECOLT-C group study. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. *Transpl Int.* 2012 Apr;25(4):448-54. doi: 10.1111/j.1432-2277.2012.01440.x. Epub 2012 Feb 21.
4. Ponziani FR, Gasbarrini A, Pompili M, Burra P, Fagioli S. Management of hepatitis C virus infection recurrence after liver transplantation: an overview. *Transplant Proc.* 2011 Jan-Feb;43(1):291-5. doi: 10.1016/j.transproceed.2010.09.102.
5. Bitetto D, De Feo T, Mantovani M, Falletti E, Fabris C, Belli LS, Fagioli S, Burra P, Piccolo G, Donato MF, Toniutto P; AISF RECOLT Study Group, Cmet S, Cussigh A, Viganò R, Airolidi A, Pasulo L, Colpanij M, De Martin E, Gambato M, Rigamonti C. Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C. *Dig Liver Dis.* 2013 Nov;45(11):927-32. doi: 10.1016/j.dld.2013.04.006. Epub 2013 May 27.

### **Submitted (under re-revision)**

1. E. De Martin. Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: Results from the AISF RECOLT-C study group.

### **Manuscripts in In preparation**

1. Maria Rendina, SVR TO ANTIVIRAL THERAPY IS HIGHLY PROTECTIVE AGAINST LIVER-RELATED DEATH IN PATIENTS WITH HCV RECURRENCE ON THE GRAFT AFTER LIVER TRANSPLANTATION (LT)
2. V. Vero et al. Is the Primary Immunosuppressive Drug (Cyclosporin a or Tacrolimus) Playing a Role on the Response to Antiviral Treatment for Post-Transplant HCV Recurrence?
3. V. Vero et al: The Presence of Diabetes Reduces SVR After Antiviral Therapy for Post-Transplant HCV Recurrence
4. V. Vero et al. SVR to Antiviral Treatment for Post-OLT Recurrent HCV Hepatitis Can Be Improved by the use of Growth Factors

### **Published ABSTRACTS (2010-2013)**

1. C D Bitetto, T De Feo, M Mantovani, E Falletti, C Fabris, LS Belli, S Fagioli ...*Interaction between calcineurin inhibitors and IL-28B rs12979860 C> T polymorphism and response to treatment for post-transplant recurrent hepatitis* Digestive and Liver Disease 2013
2. FR Ponziani, A Milani, A Gasbarrini, R Zaccaria, R Viganò, RM Iemmolo, MF Donato, M Rendina, P Toniutto, L Pasulo, MC Morelli, P Burra, L Miglioresi, M Merli, D Di Paolo, S Fagioli, M Pompili, F D'Aversa. *Long-term maintenance of svr in difficult-to-treat HCV genotypes in liver transplant recipients with HCV recurrence* Digestive and Liver Disease 45, S210, 2013
3. Francesca Romana Ponziani, Alessandro Milani, Antonio Gasbarrini, Raffaella Zaccaria, Raffaella Viganò, Rosa Maria Iemmolo, Maria F Donato, Maria Rendina, Pierluigi Toniutto, Luisa Pasulo, Maria Cristina Morelli, Patrizia Burra, Lucia Miglioresi, Manuela Merli, Daniele Di Paolo, Stefano Fagioli, Maurizio Pompili. *Long-term maintenance of SVR in difficult-to-treat HCV genotypes in liver transplant recipients with HCV recurrence*, HEPATOLOGY, Volume 56, 2012

4. Vittoria Vero, Senzolo Marco, Luisa Pasulo, Francesca Romana Ponziani, Raffaella Viganò, Maria Marino, Maria F Donato, Maria Rendina, Pierluigi Toniutto, Matteo Cescon, Patrizia Burra, Lucia Miglioresi, Valerio Giannelli, Daniele Di Paolo, Antonio Gasbarrini, Stefano Fagiuoli. SVR to Antiviral Treatment for Post-OLT Recurrent HCV Hepatitis Can Be Improved by the use of Growth Factors *Gastroenterology* Volume 142, S-1005, 2012
5. Vittoria Vero, Senzolo Marco, Luisa Pasulo, Francesca Romana Ponziani, Raffaella Viganò, Maria Marino, Maria F Donato, Maria Rendina, Pierluigi Toniutto, Matteo Cescon, Patrizia Burra, Lucia Miglioresi, Daniele Di Paolo, Valerio Giannelli, Antonio Gasbarrini, Stefano Fagiuoli. Is the Primary Immunosuppressive Drug (Cyclosporin a or Tacrolimus) Playing a Role on the Response to Antiviral Treatment for Post-Transplant HCV Recurrence? *Gastroenterology* Volume 142, S-934, 2012
6. Francesca Romana Ponziani, Brigida E Annicchiarico, Simona Di Giambenedetto, Massimo Siciliano, Maurizio Pompili, Manuela Colafigli, Salvatore Farina, Iuri Fanti, Giovanni Gasbarrini, Stefano Fagiuoli, Antonio Gasbarrini. Hepatitis C Antiviral Treatment Response is Conditioned by Patients Immunologic System, Age and Sex *Gastroenterology*, Volume , 142 Numero 5 Pagine S-959-S-960, 2012
7. Vittoria Vero, Senzolo Marco, Luisa Pasulo, Francesca Romana Ponziani, Raffaella Viganò, Maria Marino, Maria F Donato, Maria Rendina, Pierluigi Toniutto, Matteo Cescon, Patrizia Burra, Lucia Miglioresi, Daniele Di Paolo, Valerio Giannelli, Antonio Gasbarrini, Stefano Fagiuoli. The Presence of Diabetes Reduces SVR After Antiviral Therapy for Post-Transplant HCV Recurrence *Gastroenterology*, Volume 142 Numero 5 Pagine S-1004-S-1005, 2012
8. D Bitetto, E Falletti, E Fornasiere, L Belli, R Viganò, S Fagiuoli, L Pasulo, F Donato, C Rigamonti, M Rendina, E De Martin, P Burra, FR Ponziani, A Gasbarrini, S Ginanni-Corradini, S Cmet, A Cussigh, T De Feo, C Fabris, P Toniutto. INTERACTION BETWEEN CYCLOSPORINE AND RECIPIENT IL-28B RS12979860 C> T GENETIC POLYMORPHISMS IN THE ACHIEVEMENT OF SUSTAINED VIRAL RESPONSE FOR RECURRENT HEPATITIS C *Journal of Hepatology*, Volume 56 Pagine S37 2012
9. Francesca Romana Ponziani, Alessandro Milani, Antonio Gasbarrini, Raffaella Zaccaria, Raffaella Viganò, Maria Francesca Donato, Maria Cristina Morelli, Lucia Miglioresi, Luisa Pasulo, Maria Rendina, Daniele Di Paolo, Maria Marino, Pierluigi Toniutto, Stefano Fagiuoli, Maurizio Pompili. Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study. *Annals of hepatology* Volume 11, Numero, 3, pagine338, 2012
10. Valerio Giannelli, Michela Giusto, Alessio Farcomeni, Francesca R Ponziani, Maurizio Pompili, Raffaella Viganò, Rosa Maria Iemmolo, Maria F Donato, Maria Rendina, Pierluigi Toniutto, Luisa Pasulo, Maria Cristina Morelli, Eleonora De Martin, Lucia Miglioresi, Daniele Di Paolo, Stefano Fagiuoli, Manuela Merli. Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. *Transplant International* Volume 5, Numero 4 Pagine 448-454, 2012
11. FR Ponziani, BE Annicchiarico, E Di Giambenedetto, M Siciliano, M Pompili, M Colafigli, S Farina, I Fanti, G Gasbarrini, S Fagiuoli, A Gasbarrini. THE KEY ROLE OF IMMUNE SYSTEM, AGE AND SEX IN THE RESPONSE TO HEPATITIS C ANTIVIRAL TREATMENT *Digestive and Liver Disease*, Volume 44, Pagine S109, 2012
12. Francesca R Ponziani, Alessandro Milani, Antonio Gasbarrini, Raffaella Viganò, Rosa Maria Iemmolo, Maria F Donato, Maria Rendina, Pierluigi Toniutto, Luisa Pasulo, Maria Cristina Morelli, Eleonora De Martin, Lucia Miglioresi, Valerio Giannelli, Daniele Di Paolo, Stefano Fagiuoli, Maurizio Pompili. Best Matching for HCV Genotype 1 Liver Transplant Recipients is Predicted by Hcv1-Star. A Study From Aisf Recolt-C Database. *Gastroenterology* Volume 140, Numero 5, Pagine S-901, 2011
13. RM Iemmolo, M Marino, R Montalti, F Ponziani, R Viganò, E De Martin, MF Donato, M Rendina, MC Morelli, D Di Paolo, E Fornasiere, L Migliorasi, V Giannelli, S Fagiuoli, GE Gerunda. DONOR-RELATED CHARACTERISTICS AS PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE TO ANTIVIRAL THERAPY IN RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION *Journal of Hepatology* Volume 54 Pagine S225, 2011
14. M Rendina, NM Castellana, S Fagiuoli, F Ponziani, R Viganò, RM Iemmolo, MF Donato, P Toniutto, L Pasulo, MC Morelli, P Burra, L Miglioresi, V Giannelli, D Di Paolo, A Di Leo. ACUTE AND CHRONIC REJECTION DURING INTERFERON THERAPY IN HCV RECURRENT TRANSPLANT PATIENTS: RESULTS FROM THE AISF-RECOLT-C GROUP *Journal of Hepatology* Volume 54 Pagine S230, 2011

15. D Di Paolo, FR Ponziani, S Faggioli, R Viganò, RM Iemmolo, MF Ponato, M Rendina, M Cescon, P Toniutto, L Miglioresi, E De Martin, M Merli, G Tisone, M Angelico. POOR ADHERENCE TO PEGYLATED-INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE RECOLT-C GROUP *Journal of Hepatology* Volume, 54 Pagine S218, 2011
16. V Bertuzzo, R Viganò, MF Donato, M Marino, M Rendina, E Fornasiere, L Pasulo, P Burra, L Miglioresi, V Giannelli, D Di Paolo, M Pompili, FR Ponziani, S Faggioli, M Cescon. PROTRACTED ANTIVIRAL TREATMENT BEYOND CONVENTIONAL TIME LIMITS IMPROVES SURVIVAL IN NON-RESPONDERS TO INTERFERON+ RIBAVIRIN ADMINISTERED FOR HCV RECURRENCE AFTER LIVER TRANSPLANTATION *Journal of Hepatology*, Volume 54 Pagine S214-S215, 2011
17. D Di Paolo, FR Ponziani, S Faggioli, R Viganò, RM Iemmolo, MF Donato, M Rendina, MC Morelli, P Toniutto, L Miglioresi, E De Martin, M Merli, G Tisone, M Angelico. POOR ADHERENCE TO PEGYLATED INTERFERON AND RIBAVIRIN IS A MAJOR CONCERN IN THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: EVIDENCE FROM THE AISF RECOLT-C STUDY GROUP. *Digestive and Liver Disease* Volume, 43, Pagine S149, 2011
18. M Rendina, NM Castellaneta, S Faggioli, F Ponziani, R Viganò, RM Iemmolo, MF Donato, P Toniutto, L Pasulo, MC Morelli, P Burra, L Miglioresi, V Giannelli, D Di Paolo, A Di Leo. The persistence of HCV replication is associated with an increased mortality rate in HCV recurrent transplant patients: Results from the AISF-RECOLT-C group *Digestive and Liver Disease*, Volume 43 Pagine S101-S102, 2011
19. Eleonora De Martin, Marco Senzolo, Francesca R Ponziani, D Di Paolo, R Viganò, M Marino, MF Donato, M Rendina, MC Morelli, E Fornasiere, Lucia Miglioresi, V Giannelli, Stefano Faggioli, Patrizia Burra Impact of antiviral therapy on fibrosis progression due to HCV recurrence after liver transplantation: Results from the AISF RECOLT-C study group. *Digestive and Liver Disease* Volume 43, Pagine S90-S91, 2011
21. Maria Rendina, Nicola Maurizio Castellaneta, Stefano Faggioli, Patrizia Burra, Raffaella Viganò, Rosa Maria Iemmolo, Maria F Donato, Pierluigi Toniutto, Luisa Pasulo, Maria Cristina Morelli, Lucia Miglioresi, Manuela Merli, Mario Angelico, Antonio Gasbarrini, Alfredo Di Leo. SVR TO ANTIVIRAL THERAPY IS HIGHLY PROTECTIVE AGAINST LIVER-RELATED DEATH IN PATIENTS WITH HCV RECURRENCE ON THE GRAFT AFTER LIVER TRANSPLANTATION (LT) *Hepatology* Volume 52, Numero 4, Pagine 321A-322A, 2010

## **Abstracts Submitted 2014**

### **1. AISF 2014 EASL 2014 ILTS 2014**

- a. D. Bitetto<sup>1,13</sup>, V. Vero<sup>1</sup>, S. Pecere<sup>1,8</sup>, L. Belli<sup>2</sup>, R.M. Iemmolo<sup>3</sup>, M.C. Morelli<sup>4</sup>, F. Donato<sup>5</sup>, P. Burra<sup>6</sup>, M. Rendina<sup>7</sup>, F. R. Ponziani<sup>8</sup>, L. Miglioresi<sup>9</sup>, D. Di Paolo<sup>10</sup>, M. Merli<sup>11</sup>, A. Gasbarrini<sup>8</sup>, S. Ginanni-Corradini<sup>11</sup>, E. Falletti<sup>12</sup>, T. De Feo<sup>12</sup>, P. Toniutto<sup>13</sup>, S. Faggioli<sup>1</sup> The impact of IL-28B polymorphism and diabetes on SVR after antiviral therapy (AT) for post- liver transplant (LT) HCV recurrence.
- b. 1,12D. Bitetto, 1,8S. Pecere, 1L. Pasulo, 2L. Belli, 3R.M. Iemmolo, 4M.C. Morelli, 5F. Donato, 6P. Burra, 7M. Rendina, 8F.R. Ponziani, 9L. Miglioresi, 10D. Di Paolo, 11M. Merli, 8 A. Gasbarrini, 12P. Toniutto, 1S. Faggioli. Recipient and donor gender match predicts the outcome of antiviral therapy for recurrent hepatitis C